Abstract
Indobufen, an inhibitor of platelet aggregation, or a matching placebo were administered (200 mg b.i.d. by oral route) to 8 hypercholesterolemic subjects and to 8 normal volunteers, according to a randomized cross-over design for three days with a four day interval. Platelet aggregation and malondialdehyde (MDA) production by platelets were measured before and during treatment. Indobufen administration completely suppressed the aggregation of platelets induced by threshold concentrations of arachidonic acid, as well as the second wave of aggregation induced by epinephrine, up to twelve hours from drug treatment. MDA production was also completely suppressed by Indobufen administration. Platelets from type IIA patients needed lower concentrations of aggregating agents, to overcome the inhibitory effect of Indobufen.
| Original language | English |
|---|---|
| Pages (from-to) | 847-859 |
| Number of pages | 13 |
| Journal | Pharmacological Research Communications |
| Volume | 13 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1981 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Indobufen treatment in type iia hypercholesterolemic subjects : Effects on platelet function and malondialdehyde production. / Tremoli, E.; Maderna, P.; Sirtori, M.; Colli, S.; Corvi, G.; Sirtori, C. R.
In: Pharmacological Research Communications, Vol. 13, No. 9, 1981, p. 847-859.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Indobufen treatment in type iia hypercholesterolemic subjects
T2 - Effects on platelet function and malondialdehyde production
AU - Tremoli, E.
AU - Maderna, P.
AU - Sirtori, M.
AU - Colli, S.
AU - Corvi, G.
AU - Sirtori, C. R.
PY - 1981
Y1 - 1981
N2 - Indobufen, an inhibitor of platelet aggregation, or a matching placebo were administered (200 mg b.i.d. by oral route) to 8 hypercholesterolemic subjects and to 8 normal volunteers, according to a randomized cross-over design for three days with a four day interval. Platelet aggregation and malondialdehyde (MDA) production by platelets were measured before and during treatment. Indobufen administration completely suppressed the aggregation of platelets induced by threshold concentrations of arachidonic acid, as well as the second wave of aggregation induced by epinephrine, up to twelve hours from drug treatment. MDA production was also completely suppressed by Indobufen administration. Platelets from type IIA patients needed lower concentrations of aggregating agents, to overcome the inhibitory effect of Indobufen.
AB - Indobufen, an inhibitor of platelet aggregation, or a matching placebo were administered (200 mg b.i.d. by oral route) to 8 hypercholesterolemic subjects and to 8 normal volunteers, according to a randomized cross-over design for three days with a four day interval. Platelet aggregation and malondialdehyde (MDA) production by platelets were measured before and during treatment. Indobufen administration completely suppressed the aggregation of platelets induced by threshold concentrations of arachidonic acid, as well as the second wave of aggregation induced by epinephrine, up to twelve hours from drug treatment. MDA production was also completely suppressed by Indobufen administration. Platelets from type IIA patients needed lower concentrations of aggregating agents, to overcome the inhibitory effect of Indobufen.
UR - http://www.scopus.com/inward/record.url?scp=0019869275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019869275&partnerID=8YFLogxK
U2 - 10.1016/S0031-6989(81)80045-8
DO - 10.1016/S0031-6989(81)80045-8
M3 - Article
C2 - 7335762
AN - SCOPUS:0019869275
VL - 13
SP - 847
EP - 859
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
IS - 9
ER -